Every 424B that Genprex Inc (GNPX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow GNPX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GNPX filings page.
Genprex, Inc. is registering the offer and sale of up to $75,000,000 of additional common stock under an at-the-market offering agreement with H.C. Wainwright & Co. This prospectus supplement updates prior prospectuses and reflects a one-for-fifty reverse stock split of Genprex’s common stock effective October 21, 2025. The company’s common stock trades on the Nasdaq Capital Market under the symbol GNPX, and the last reported sale price on November 21, 2025 was $3.00 per share. The securities are described as involving a high degree of risk, with detailed risk factors incorporated by reference.
Genprex, Inc. filed a prospectus supplement for an at‑the‑market offering of up to $11,495,368 of common stock under its Sales Agreement with H.C. Wainwright & Co., to be sold from time to time.
The company updated its public float to $81.7 million as of November 7, 2025, calculated from 1,944,732 shares held by non‑affiliates at $42.00 (the October 15, 2025 closing price), and stated it is no longer subject to General Instruction I.B.6 sales limitations. Through the date hereof, it has sold 492,508 shares under the Sales Agreement pursuant to prior prospectuses. The supplement also reflects a 1‑for‑50 reverse stock split effective October 21, 2025. Genprex’s common stock trades on Nasdaq as “GNPX”; the last reported sale price on November 10, 2025 was $4.00 per share.
Genprex, Inc. priced a primary offering of 377,780 shares of common stock at $9.00 per share, for gross proceeds of $3,400,020. After placement agent fees of $0.63 per share, the company expects proceeds before expenses of $3,162,018.60. Net proceeds are estimated at approximately $3.0 million, earmarked for working capital and general corporate purposes. Shares outstanding were 1,254,061 before the offering and are expected to be 1,631,841 immediately after.
In a concurrent private placement, purchasers will receive warrants to buy up to 755,560 shares at an exercise price of $8.75 per share; these warrants and their underlying shares are not registered here. Genprex will also issue placement agent warrants for up to 22,667 shares at $11.25 per share. The company recently effected a 1‑for‑50 reverse stock split (October 21, 2025) following a 1‑for‑40 split in 2024, and continues to work toward Nasdaq listing compliance. The common stock trades on Nasdaq under “GNPX”.
Genprex, Inc. is conducting a primary offering of 243,622 shares of common stock at $11.21 per share, for gross proceeds of $2,731,002.62. After placement agent fees and estimated offering expenses, the company expects net proceeds of approximately $2.3 million. The offering is being executed on a reasonable best‑efforts basis by H.C. Wainwright & Co.
In a concurrent private placement, purchasers will receive unregistered warrants to buy up to 487,244 shares at an $11.00 exercise price. Shares outstanding were 1,004,437 before the transaction and are expected to be 1,248,059 after the offering. Genprex recently effected 1‑for‑50 and 1‑for‑40 reverse stock splits and has an active Nasdaq compliance plan. The company plans to use proceeds for working capital and general corporate purposes.